All In Biotech

Drug Trial Radar · NCT00364351

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jan 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,574 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,574

Actual

Start

Aug 2006

Primary completion

Sep 2008

Study completion Nov 2016

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Aug 15, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • VandetanibDrug

    once daily oral tablet

  • ErlotinibDrug

    oral dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: progressionRECIST tumour assessments carried out every 4 weeks up to week 16 then every 8 weeks thereafter from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first, assessed.

Locations

153 sites in 22 countries. Site status is shown where the registry gives one.

  • Research Site

    Berkeley, California

  • Research Site

    Los Angeles, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Fort Myers, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Port Saint Lucie, Florida

  • Research Site

    Wichita, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Louisville, Kentucky

  • Research Site

    Metairie, Louisiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Columbia, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Latham, New York

  • Research Site

    Hickory, North Carolina

  • Research Site

    Canton, Ohio

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Greenville, South Carolina

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Amarillo, Texas

  • Research Site

    Garland, Texas

  • Research Site

    Webster, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Norfolk, Virginia

  • Research Site

    Richmond, Virginia

  • Research Site

    Burien, Washington

  • Research Site

    Yakima, Washington

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    Manuel B. Gonnet, Argentina

  • Research Site

    Ramos Mejía, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Santa Fe, Argentina

  • Research Site

    Ashford, Australia

  • Research Site

    Bedford Park, Australia

  • Research Site

    Chermside, Australia

  • Research Site

    Geelong, Australia

  • Research Site

    Hornsby, Australia

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.